PEN
Penumbra·NYSE
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 6
Bearish signal 1
Consensus Rating "Strong Buy"
MACD Golden Cross
Ample Liquidity
High Gross Profit Margin
High Cash/net Profit Ratio
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PEN
Penumbra, Inc.
A global healthcare company that develops medical devices used for neuro and peripheral vascular conditions and diseases
Healthcare Equipment and Supplies
--
09/18/2015
New York Stock Exchange
4,500
12-31
Common stock
One Penumbra Place
, 1351 Harbor Bay Parkway
, Alameda
, CA 94502
--
Penumbra, Inc., was incorporated in 2004 as a Delaware corporation. The company is a global interventional therapy company focused on the design, development, manufacture and sale of innovative medical devices. The company has a broad product portfolio of nerves and peripheral blood vessels to address challenging medical conditions and significant clinical needs across two major markets. Its product addresses include ischemic stroke, hemorrhagic stroke, and various peripheral blood vessels that can be treated through thrombosis and embolization procedures.
Earnings Call
Q2/2025
Estimate EPS0.82
Actual EPS0.86
Estimate Revenue327.37M
Actual Revenue339.50M
Penumbra's Q2 2025: Dissecting Contradictions on Thunderbolt FDA Review, Revenue Guidance, and Market Dynamics
Jul 29,2025 09:56
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS0.92
Actual EPS0.97
Estimate Revenue340.78M
Actual Revenue354.69M
Penumbra's Q3 2025 Earnings Call: Contradictions on Thunderbolt FDA Timeline, Sales Force Split, and Market Share Growth
Nov 05,2025 07:46
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
PEN has released its 2025 Q3 earnings. EPS was reported at 0.97, versus the expected 0.92, beating expectations. The chart below visualizes how PEN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
PEN has released its 2025 Q3 earnings report, with revenue of 354.69M, reflecting a YoY change of 17.82%, and net profit of 45.85M, showing a YoY change of 55.28%. The Sankey diagram below clearly presents PEN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
